Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target
- PMID: 29097143
- PMCID: PMC6166407
- DOI: 10.1016/j.steroids.2017.10.013
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target
Abstract
Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transmembrane protein enriched on the cell surface of cancer cells, including melanoma, glioblastoma, and triple-negative breast cancer. There is growing evidence identifying GPNMB as a tumor-promoter; however, despite its biological and clinical significance, the molecular mechanisms engaged by GPNMB to promote tumorigenesis are not well understood. GPNMB promotes aggressive behaviors such as tumor cell proliferation, migration, and invasion. The extracellular domain of GPNMB shed from the cell surface interacts with integrins to facilitate in the recruitment of immune-suppressive and pro-angiogenic cells to the tumor microenvironment, thereby enhancing tumor migration and invasion. GPNMB also modulates receptor tyrosine kinases and integrin signaling in a cell autonomous fashion, leading to downstream kinase signaling that in turn triggers the expression and secretion of tumorigenic factors such as matrix metalloproteinases (MMPs) and cytokines. Therefore, GPNMB exerts its pro-tumorigenic role both intracellularly and in a paracrine fashion through shedding its extracellular domain. This review highlights the importance of GPNMB in cancer progression and discusses molecular mediators of GPNMB-induced tumor growth and invasion.
Keywords: Antibody-drug conjugate; Breast cancer; GPNMB; Invasion; Matrix metalloproteinase; Melanoma.
Copyright © 2017. Published by Elsevier Inc.
Figures
References
-
- Pollack VA, et al., Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB, Cancer Chemother. Pharmacol 60 (3) (2007) 423–435. - PubMed
-
- Weterman MA, et al., nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts, Int. J. Cancer 60 (1) (1995) 73–81. - PubMed
-
- Rose AA, et al., Osteoactivin promotes breast cancer metastasis to bone, Mol. Cancer Res 5 (10) (2007) 1001–1014. - PubMed
-
- Tse KF, et al., CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma, Clin. Cancer Res 12 (4) (2006) 1373–1382. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
